UVDI-360 Room Sanitizer Inactivates SARS-CoV-2 at 12 Feet Distance in 5 Minutes

UltraViolet Devices Inc. (UVDI) has announced that its UVDI-360 Room Sanitizer achieved greater than 99.99%, or 4log10, inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in 5 minutes at a distance of 12 feet (3.65 meters).

oneSOURCE Creates Free Resource Page with Up-to-Date COVID-19 Vaccine Information

Today, oneSOURCE, an RLDatix company and leading healthcare management solution, announced a new COVID-19 vaccine resource page to assist healthcare professionals during the initial administration phases of the vaccine.

STERIS to Acquire Cantel Medical

STERIS plc and Cantel Medical Corp. announced that STERIS has signed a definitive agreement to acquire Cantel, through a U.S. subsidiary. Cantel is a global provider of infection prevention products and services primarily to endoscopy and dental Customers.

NEC Releases ‘WISE VISION Endoscopy’ in Europe and Japan

NEC Corporation has announced the development of “WISE VISION Endoscopy,” an AI diagnosis-support medical device software for colonoscopies, which is being released in Japan and is expected to soon be available in Europe.

Smart Tattoo Sensors and Continuous Vital Signs Monitoring

The measurement of vital signs is critical for medical professionals to be able to assess the general health of patients and detect any possible health deterioration as early as possible. However, standard holster devices are bulky and uncomfortable for the patient while providing only a snapshot of limited information during the brief time they are worn.

Umana T1 is a new clinical grade solution which addresses these challenges directly by using tattoo sensors made from an almost imperceptible clear film with conductive sensors. Having launched an independent clinical trial with 2,000 patients at the national hospital in Malta and working on collaborative projects in Portugal and the United Kingdom, the Umana T1 Heart Monitor will be launched across Europe in May 2018.

Commenting on this innovation, Dr. Samuel Meilak, who is coordinating the trial, notes that “our cardiology staff is excited about what the Umana T1 means for our profession and our patients. Finally, we are able to accurately collect and monitor patients’ important medical data without interfering with their day-to-day activities. The ease of access, coupled with the data analysis capabilities are complete game changers.”

Once the tattoo is applied, a small lightweight device is attached to store and share a stream of accurate real-time vital signs such as ECG data as well other vital parameters such as respiration rate. These are than shared directly with a trusted medical professional. This user-friendly setup is completed with an ecosystem of medical software, a smartphone application, online dashboards, data-analysis algorithms, online and offline data access.

Umana Co-Founder and CEO Dr. Adrian Attard Trevisan elaborates: “The tattoo sensors represent a giant leap forward for how vital signs can be continuously monitored but we went even further, with comprehensive digital data storage and processing infrastructure to allow medical professionals to get an unprecedented in-depth view and analysis of the patient’s status.”

Key members of the Umana team will be attending the HIMSS Conference in Barcelona in late May. The team will also be discussing the ways in which implementation of Umana T1 ensures better quality patient care and will be exploring potential research collaborations in further developing non-invasive methods for collecting, monitoring and analyzing long-term vital parameters.



Submit a Comment

Your email address will not be published. Required fields are marked *